Building upon our comprehensive in vitro and in vivo findings, we discuss the implications of NDUFS8 dysregulation in HCC and its potential as a therapeutic target.Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide, with HCC being the most common subtype of liver cancer. Here, NDUFS8 is linked to liver cancer.